Navidea Biopharmaceuticals INAVBQ
13F holders, Q4 2024 (December 31)1holders −1
0new positions
2sold out
$0.00avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Navidea Biopharmaceuticals I (NAVBQ) in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 2 sold out. The largest holder was Runnymede Capital Advisors, Inc. ($0).
- Company
- Navidea Biopharmaceuticals I
- CUSIP
- 63937X202
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 360 shares sold, net −360 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Runnymede Capital Advisors, Inc. | 0.00% | — | 5 | $0 |
"% of holder's portfolio" is NAVBQ's weight in each manager's 13F, not the share of Navidea Biopharmaceuticals I the manager owns.